Kangantu Secures RMB 12 Million Series A from Oriental Fortune Capital to Build Global Marketing Network and Medical Resource Database
On December 6, Kangantu, a cross-border healthcare service provider specializing in facilitating liver disease treatment in India, secured RMB 12 million in its first round of financing from Oriental Fortune Capital. Yang Chen, founder of Kangantu, told VCBeat (WeChat ID: vcbeat) that the funds will be used to build a global marketing network and establish a comprehensive global medical resources database.
Yang Chen, Founder of Kangantu
Kangantu was established in May 2015 by a team of PhD researchers from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, who have long been at the forefront of hepatitis C research. It is the first company in China to professionally guide patients to India for treatment with the latest hepatitis C regimens. To date, it has affiliated teams in 18 provinces and municipalities across China, formed more than 70 hepatitis C treatment groups, and facilitated overseas hepatitis C treatment for over 700 patients.Accounting for over 60% of the entire niche market, it ranks first in the industry for hepatitis C treatment in India.。
Kangantu has extensive experience in managing hepatitis C treatment for Chinese patients using medications such as sofosbuvir, Harvoni (ledipasvir/sofosbuvir), and daclatasvir. It has established comprehensive partnerships with multiple top-tier Indian hospitals, including MAX, Medanta, and Fortis. For patients with all genotypes of hepatitis C, interferon-free, all-oral regimens are available, achieving cure rates exceeding 95%.
Kangantu offers a one-stop service for hepatitis C treatment in India, handling Indian visa applications, round-trip flight bookings, and providing full-process accompaniment by a Ph.D. holder for medical consultations, medication pickup, and assistance with accommodation, meals, and transportation. The total cost is only RMB 38,000. The Ph.D. team provides free follow-up consultation services on medication. Currently, in addition to facilitating hepatitis C treatment in India, Kangantu also offers services for cancer treatment, international patient referrals, and overseas fertility treatments.
Regarding the Development of a Global Marketing Network, Yang Chen stated that Kangantu has already established its own marketing teams in the United States, Taiwan (China), South Korea, and other regions, and has currently provided medical travel services to India for more than 10 overseas patients. A portion of the funds from this financing round will be allocated to the development of overseas marketing teams and channels.
Regarding the development of its domestic marketing team, Yang Chen stated that the focus will be on training employees in medical knowledge. While most of the company’s management and founding team have medical backgrounds, part-time staff and some employees lack sufficient professional medical expertise. Currently, Kang’antu has developed internal training courses and is conducting employee training.
In addition to training employees, Kangantu also recruits franchisees across different regions of China. Currently, Kangantu has 18 franchisees, and Yang Chen expressed hope to achieve nationwide coverage as soon as possible.
Another use of this financing is to build a global big data platform for medical resources.By deeply mining approximately 27 million scientific research papers and various data sources, Kangantu is analyzing indicators such as new drug developments, medical pricing, incidence rates, and insurance coverage across different countries. It is building a global healthcare information big database and an artificial intelligence platform to identify the most cost-effective cross-border medical consultation solutions for patients.
Big data-assisted decision-making not only benefits patients but also significantly supports the business expansion of Kangantu. For instance, by understanding the incidence rates of specific diseases in a given region, Kangantu can precisely target its disease-specific services to that area, thereby helping the company substantially reduce costs.
Why It Has Garnered Favor from Capital, Yang Chen Told Reporters,Oriental Fortune Capital’s primary focus is not on their cash flow, but rather on their team with a medical background., VCBeat previously in “Kangantu: The Industry Leader in Hepatitis C Treatment in India, Capturing Over 60% of the Niche Market ShareThe article points out that Kangantu’s founding team all have medical backgrounds and are experts in medical informatics. What Kangantu aims to do is to genuinely diagnose and treat patients while saving costs, rather than providing superficial solutions. They merely use the internet as an efficient tool or channel to connect patients with doctors and pharmaceutical resources; ultimately, their core business is disease treatment. Therefore, a team with medical expertise constitutes their inherent advantage. This is also why Kangantu has invested heavily in providing professional knowledge training for its employees.